Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Estimating Treatment Effect With Clinical Interpretation From a Comparative Clinical Trial With an End Point Subject to Competing Risks.

× No keyword cloud information.

5 in total

1. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure.

Authors: Eric J Eichhorn; Michael J Domanski; Heidi Krause-Steinrauf; Michael R Bristow; Philip W Lavori
Journal: N Engl J Med Date: 2001-05-31 Impact factor: 91.245

2. Restricted Mean Survival Time as a Measure to Interpret Clinical Trial Results.

Authors: Dae Hyun Kim; Hajime Uno; Lee-Jen Wei
Journal: JAMA Cardiol Date: 2017-11-01 Impact factor: 14.676

3. Competing risk regression models for epidemiologic data.

Authors: Bryan Lau; Stephen R Cole; Stephen J Gange
Journal: Am J Epidemiol Date: 2009-06-03 Impact factor: 4.897

4. Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies.

Authors: Hajime Uno; Janet Wittes; Haoda Fu; Scott D Solomon; Brian Claggett; Lu Tian; Tianxi Cai; Marc A Pfeffer; Scott R Evans; Lee-Jen Wei
Journal: Ann Intern Med Date: 2015-07-21 Impact factor: 25.391

5. Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome.

Authors: Patrick Royston; Mahesh K B Parmar
Journal: BMC Med Res Methodol Date: 2013-12-07 Impact factor: 4.615

5 in total

7 in total

1. Implementation of an Alternative Method for Assessing Competing Risks: Restricted Mean Time Lost.

Authors: Hongji Wu; Hao Yuan; Zijing Yang; Yawen Hou; Zheng Chen
Journal: Am J Epidemiol Date: 2022-01-01 Impact factor: 5.363

2. Novel Risk Modeling Approach of Atrial Fibrillation With Restricted Mean Survival Times: Application in the Framingham Heart Study Community-Based Cohort.

Authors: Laila Staerk; Sarah R Preis; Honghuang Lin; Juan P Casas; Kathryn Lunetta; Lu-Chen Weng; Christopher D Anderson; Patrick T Ellinor; Steven A Lubitz; Emelia J Benjamin; Ludovic Trinquart
Journal: Circ Cardiovasc Qual Outcomes Date: 2020-03-31

3. Counterfactual mediation analysis in the multistate model framework for surrogate and clinical time-to-event outcomes in randomized controlled trials.

Authors: Isabelle R Weir; Jennifer R Rider; Ludovic Trinquart
Journal: Pharm Stat Date: 2021-08-04 Impact factor: 1.894

Estimating Treatment Effect With Clinical Interpretation From a Comparative Clinical Trial With an End Point Subject to Competing Risks.

1. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure.

2. Restricted Mean Survival Time as a Measure to Interpret Clinical Trial Results.

3. Competing risk regression models for epidemiologic data.

4. Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies.

5. Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome.

1. Implementation of an Alternative Method for Assessing Competing Risks: Restricted Mean Time Lost.

2. Novel Risk Modeling Approach of Atrial Fibrillation With Restricted Mean Survival Times: Application in the Framingham Heart Study Community-Based Cohort.

3. Counterfactual mediation analysis in the multistate model framework for surrogate and clinical time-to-event outcomes in randomized controlled trials.

4. Statistical Issues and Lessons Learned From COVID-19 Clinical Trials With Lopinavir-Ritonavir and Remdesivir.

Review 5. How to Quantify and Interpret Treatment Effects in Comparative Clinical Studies of COVID-19.

6. The use of restricted mean time lost under competing risks data.

7. Estimation and modeling of the restricted mean time lost in the presence of competing risks.